Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | KIF5B | P33176 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | ETV6 | P41212 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21513351 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2D6CYP2C19TDP1HRH3 | |
| SCHEMBL30866911 | 0.84 | CYP1A2 (0.43) | CYP1A2CYP2D6CYP2C19TDP1HRH3 | |
| SCHEMBL21513134 | 0.84 | CYP1A2 (0.43) | CYP1A2CYP2D6CYP2C19TDP1HRH3 | |
| SCHEMBL21513348 | 0.81 | KDM4E (0.48) | CYP1A2CYP2D6CYP2C19TDP1HRH3 | |
| SCHEMBL29969562 | 0.81 | KDM4E (0.48) | CYP1A2CYP2D6CYP2C19TDP1HRH3 | |
| SCHEMBL611785 | 0.81 | PIK3CA (0.37) | TDP1KDRALDH1A1 | |
| SCHEMBL188553 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2A | |
| SCHEMBL21512638 | 0.80 | KDM4E (0.46) | CYP1A2CYP2D6CYP2C19TDP1HRH3 | |
| SCHEMBL21512755 | 0.80 | HRH3 (0.42) | CYP1A2CYP2D6CYP2C19HRH3KDM4E | |
| SCHEMBL30866883 | 0.80 | KDM4E (0.46) | CYP1A2CYP2D6CYP2C19TDP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | CYP1A2 3864/4885CYP2D6 3524/4885CYP2C19 3574/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | CYP1A2 3864/4885CYP2D6 3524/4885CYP2C19 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.